Simb16: Modeling induced immune system response against B16-melanoma

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Pappalardo, Francesco ^a   Forero, Ivan Martinez ^b   Pennisi, Marzio ^a   Palazon, Asis ^b   Melero, Ignacio ^b   Motta, Santo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CD137 ANTIGEN; MONOCLONAL ANTIBODY CD137; OT 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CELL INTERACTION; CELL THERAPY; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; INTERMETHOD COMPARISON; LYMPHOCYTE ACTIVATION; MELANOMA B16; MOUSE; NONHUMAN; PREDICTION; PROTEIN LOCALIZATION; TREATMENT PLANNING; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; ENDOTHELIUM CELL; EXPERIMENTAL MELANOMA; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD137; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; IMMUNE SYSTEM; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80054779529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026523     Document Type: Article

References (28)

1. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
3. Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazon A, et al. (2009) Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination. Clin Cancer Res 15: 1507-1509.
4. Perez-Gracia JL, Berraondo P, Martinez-Forero I, Alfaro C, Suarez N, et al. (2009) Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy 1: 845-853.
5. Tirapu I, Arina A, Mazzolini G, Duarte M, Alfaro C, et al. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 110: 51-60.
6. Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, et al. (2006) Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 66: 2442-2450.
7. Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, et al. (2011) Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 71: 801-811.
8. Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H, (2001) CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 115: 543-549.
9. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL, (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 29: 383-390.
10. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685.
11. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L, (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7: 95-106.
12. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, et al. (2004) Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 64: 8411-8419.
13. May KF Jr, Chen L, Zheng P, Liu Y, (2002) Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 62: 3459-3465.
14. Dubrot J, Milheiro F, Alfaro C, Palazon A, Martinez-Forero I, et al. (2010) Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 59: 1223-1233.
15. Melief CJ, (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
16. Pappalardo F, Pennisi M, Castiglione F, Motta S, (2010) Vaccine protocols optimization: in silico experiences. Biotechnol Adv 28: 82-93.
17. Pappalardo F, Musumeci S, Motta S, (2008) Modeling immune system control of atherogenesis. Bioinformatics 24: 1715-1721.
18. Castiglione F, Pappalardo F, Bernaschi M, Motta S, (2007) Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics 23: 3350-3355.
19. Motta S, Castiglione F, Lollini P, Pappalardo F, (2005) Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res 1: 5.
20. Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, et al. (2010) In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res 70: 7755-7763.
21. Baldazzi V, Paci P, Bernaschi M, Castiglione F, (2009) Modeling lymphocyte homing and encounters in lymph nodes. BMC Bioinformatics 10: 387.
22. Olofsson PS, Soderstrom LA, Wagsater D, Sheikine Y, Ocaya P, et al. (2008) CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117: 1292-1301.
23. Pappalardo F, Lefranc M, Lollini PL, Motta S, (2010) A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY. Immunome Research, 6: 1.
24. Pappalardo F, Mastriani E, Lollini PL, Motta S, (2005) Genetic Algorithm Against Cancer. Lecture Notes in Artificial Intelligence 3849: 223-228.
25. Pennisi M, Catanuto R, Pappalardo F, Motta S, (2008) Optimal vaccination schedules using simulated annealing. Bioinformatics 24: 1740-1742.
26. Pappalardo F, Halling-Brown M, Rapin N, Zhang P, Alemani D, et al. (2009) ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Briefings in Bioinformatics 10: 330-340.
27. Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, et al. (2010) ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos T R Soc A 368: 2799-2815.
28. Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, et al. (2010) Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics 11 (Suppl 7): S13.